Cited by 550Gastrointestinal motility and disordersStatistical Methods in Clinical TrialsEthics in Clinical Research

The DOI matches its Crossref record; 147 of the 151 references it cites were found in a registry or an index.

Design of Treatment Trials for Functional Gastrointestinal Disorders

Irvine, E. Jan, Tack, Jan, Crowell, Michael D., Gwee, Kok Ann, Ke, Meiyun, Schmulson, Max J., Whitehead, William E., Spiegel, Brennan·2016·Gastroenterology

DOI 10.1053/j.gastro.2016.02.010

Open this paper in CoChat — free account

Abstract

This article summarizes recent progress and regulatory guidance on design of trials to assess the efficacy of new therapies for functional gastrointestinal disorders (FGIDs). The double-masked, placebo-controlled, parallel-group design remains the accepted standard for evaluating treatment efficacy. A control group is essential, and a detailed description of the randomization process and concealed allocation method must be included in the study report. The control will most often be placebo, but for therapeutic procedures and for behavioral treatment trials, respectively, a sham procedure and control intervention with similar expectation of benefit, but lacking the treatment principle, are recommended. Investigators should be aware of, and attempt to minimize, expectancy effects (placebo, nocebo, precebo). The primary analysis should be based on the proportion of patients in each treatment arm who satisfy a treatment responder definition or a prespecified clinically meaningful change in a patient-reported outcome measure. Data analysis should use the intention-to-treat principle. Reporting of results should follow the Consolidated Standards for Reporting Trials guidelines and include secondary outcome measures to support or explain the primary outcome and an analysis of harms data. Trials should be registered in a public location before initiation and results should be published regardless of outcome.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2016.02.010

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Untitled work
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
The McGill Pain Questionnaire: Major properties and scoring methods
Melzack, R. (1975) · Pain · doi:10.1016/0304-3959(75)90044-5 · Cited by 6,873
Multilevel analysis : an introduction to basic and advanced multilevel modeling
Snijders, T. A. B., & Bosker, R. (1999) · Cited by 6,830
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Measurement of health status
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Sickness Impact Profile: Development and Final Revision of a Health Status Measure
Bergner, M., Bobbitt, R. A., Carter, W. B., & Gilson, B. S. (1981) · Medical Care · doi:10.1097/00005650-198108000-00001 · Cited by 4,619
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
The MOS Short-form General Health Survey: Reliability and Validity in a Patient Population
Stewart, A. L., Hays, R. D., & Ware, J. E. (1988) · Medical Care · doi:10.1097/00005650-198807000-00007 · Cited by 3,339

Flagged first, then by citations

Show all 151 references

4 of the 151 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 550

Evaluation of Benefit and Tolerability of IQP‐CL‐101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double‐Blinded, Randomised, Placebo‐Controlled Clinical Trial
Alt, F., Chong, P.-W., Teng, E., & Uebelhack, R. (2017) · Phytotherapy Research · doi:10.1002/ptr.5826 · Cited by 26
Clinical trial design in adult reflux disease: a methodological workshop
Dent, J., Kahrilas, P. J., Vakil, N. B., van Zanten, S. V., Bytzer, P. M., Delaney, B. C., Haruma, K., Hatlebakk, J. G., McColl, E., Moayyedi, P., et al. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03700.x · Cited by 25
Self-citation
Bioecological control of inflammatory bowel disease
Bengmark, S. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.10.001 · Cited by 25
A systematic review of tegaserod for the treatment of irritable bowel syndrome
Jones, B. W., Moore, D., Robinson, S., & Song, F. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00426.x · Cited by 25
In Vivo, Proteomic, and In Silico Investigation of Sapodilla for Therapeutic Potential in Gastrointestinal Disorders
Ansari, S. F., Khan, A., Qazi, N. G., Shah, F. A., & Naeem, K. (2019) · BioMed Research International · doi:10.1155/2019/4921086 · Cited by 24
Fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials
Samuthpongtorn, C., Kantagowit, P., Pittayanon, R., Patcharatrakul, T., & Gonlachanvit, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1039284 · Cited by 24
“Eight to 12 weeks’ outcomes were classified as “shortterm” and 6–12 months as “long-term” (26, 27).”
Systematic Review of Randomized Controlled Trials: Fiber Supplements for Abdominal Pain-Related Functional Gastrointestinal Disorders in Childhood
Horvath, A., Dziechciarz, P., & Szajewska, H. (2012) · Annals of Nutrition and Metabolism · doi:10.1159/000338965 · Cited by 24
Self-Efficacy in Children with Functional Constipation Is Associated with Treatment Success
Santucci, N. R., Rein, L. E., van Tilburg, M. A. L., Karpinski, A. C., Rosenberg, A. J., Amado-Feeley, A., Stoops, E., Herdes, R. E., & Hyman, P. E. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.08.062 · Cited by 24
Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies
Bresson, J., Flynn, A., Heinonen, M., Hulshof, K. F. A. M., Korhonen, H. J. T., Marchelli, R., Martin, A., Moseley, B. E. B., Przyrembel, H., Salminen, S., et al. (2008) · Cited by 24
Evaluating when and why patients discontinue chronic therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation
Shah, E. D., Suresh, S., Jou, J., Chey, W. D., & Stidham, R. W. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000530 · Cited by 23
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist s in people with type 2 diabetes mellitus: A network meta‐analysis
Rayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
“Limitations include both the variability in definitions of GI AEs and the self-reporting of GI AEs, which may be influenced either by the expectation that they will occur (nocebo effect) or by an opinion that one treatment is less likely to cause GI AEs than another (precebo effect).(43) Other limitations include the…”
H 2 receptor antagonists and prokinetics in dyspepsia: a critical review
Bytzer, P. M. (2002) · Gut · doi:10.1136/gut.50.suppl_4.iv58 · Cited by 23
Persistent Dyspepsia After Laparoscopic Cholecystectomy. The Influence of Psychological Factors
Lorusso, D., Porcelli, P., Pezzolla, F., Lantone, G., Zivoli, G., Guerra, V., Misciagna, G., & Demma, I. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310002995 · Cited by 23
Treatment for Bacterial Overgrowth in the Irritable Bowel Syndrome
Drossman, D. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00012 · Cited by 24
Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID
Chang, L., & Drossman, D. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.49 · Cited by 22
Skills or Pills: Randomized Trial Comparing Hypnotherapy to Medical Treatment in Children With Functional Nausea
Browne, P. D., de Bruijn, C. M. A., Speksnijder, E. M., den Hollander, B., van Wering, H. M., Wessels, M. M. S., Groeneweg, M., Goede, J., Frankenhuis, C., Tromp, E., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.10.029 · Cited by 22
Gut-Directed Pelvic Floor Behavioral Treatment for Fecal Incontinence and Constipation in Patients with Inflammatory Bowel Disease
Khera, A. J., Chase, J. W., Salzberg, M. R., Thompson, A. J. V., & Kamm, M. A. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy344 · Cited by 22
Comparison of a Chinese Herbal Medicine (CCH1) and Lactulose as First-Line Treatment of Constipation in Long-Term Care: A Randomized, Double-Blind, Double-Dummy, and Placebo-Controlled Trial
Huang, C.-H., Lin, J., Li, T., Lee, S.-C., Wang, H. P., Lue, H., & Su, Y. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/923190 · Cited by 22
TEGASEROD: A NOVEL, SELECTIVE 5‐HT4 RECEPTOR PARTIAL AGONIST FOR IRRITABLE BOWEL SYNDROME
Beglinger, C. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11190.x · Cited by 22
Nurse-Administered, Gut-Directed Hypnotherapy in IBS: Efficacy and Factors Predicting a Positive Response
Lövdahl, J., Ringström, G., Agerforz, P., Törnblom, H., & Simrén, M. (2015) · American Journal of Clinical Hypnosis · doi:10.1080/00029157.2015.1030492 · Cited by 24
Procedures in Fecal Microbiota Transplantation for Treating Irritable Bowel Syndrome: Systematic Review and Meta-Analysis
Rodrigues, T., Fialho, S. R., Araújo, J. R., Rocha, R., & Moreira-Rosário, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051725 · Cited by 21
Measuring dyspepsia: a new severity index validated in Bologna
Luca, L. D., Zagari, R. M., Pozzato, P., Fiorini, T., Ricciardiello, L., Martuzzi, C., Roda, E., Bazzoli, F., & van Zanten, S. J. O. V. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.07.010 · Cited by 21
Clinical characteristics of functional dyspepsia depending on chemosensitivity to capsaicin
Hammer, J., & Führer, M. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13103 · Cited by 21
Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole - results from the STARS II study
van Zanten, S. V., Wahlqvist, P., Talley, N. J., Halling, K., Vakil, N. B., Lauritsen, K., Flook, N. W., Persson, T., Bolling‐Sternevald, E., & on behalf of the STARS II Investigators (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04789.x · Cited by 21
Systematic Review: FDA-Approved Prescription Medications for Adults With Constipation.
Cash, B. D., & Lacy, B. E. (2006) · Europe PMC (PubMed Central) · Cited by 21
Role of psychological questionnaires in clinical practice and research within functional gastrointestinal disorders
Luo, Y., & Keefer, L. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14297 · Cited by 23
Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial
Nardo, G. D., Oliva, S., Ferrari, F., Mallardo, S., Barbara, G., Cremon, C., Aloi, M., & Cucchiara, S. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-142 · Cited by 20
Fecal microbiota transfer for bowel disorders: efficacy or hype?
Schmulson, M. J., & Bashashati, M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.08.012 · Cited by 20
Self-citation
Development of a Core Outcome Set for Infant Gastroesophageal Reflux Disease
Singendonk, M. M. J., Rexwinkel, R., Steutel, N. F., Gottrand, F., McCall, L., Orsagh-Yentis, D. K., Rosen, R., Strisciuglio, C., Thapar, N., Vandenplas, Y., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002245 · Cited by 20
The use of recombinant human bone morphogenetic protein-2 for the repair of extraction socket defects: a technical modification and case series report.
Misch, C. M. (2010) · PubMed · Cited by 20
Identifying responders to acid suppression in dyspepsia using a random starting day trial
THE DANISH DYSPEPSIA STUDY GROUP:, Bytzer, P. M., Hansen, J. M., Rune, S. J., Bonnevie, O., Breinstrup, H., Funch-Jensen, P. M., Matzen, P., Meineche-Schmidt, V., & de Muckadell, O. B. S. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00866.x · Cited by 20
On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain
Lacy, B. E., On behalf of the study group, Wang, F., Bhowal, S., & Schaefer, E. (2013) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.804117 · Cited by 20
Editorial: Is Adequate Relief Fatally Flawed or Adequate as an End Point in Irritable Bowel Syndrome?
Camilleri, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.20 · Cited by 16
Acupuncture for functional dyspepsia: study protocol for a two-center, randomized controlled trial
Han, G., Ko, S., Park, J.-W., Kim, J., Yeo, I., Lee, H., Kim, S., & Lee, H. (2014) · Trials · doi:10.1186/1745-6215-15-89 · Cited by 18
Effectiveness of sacral nerve stimulation in fecal incontinence after multimodal oncologic treatment for pelvic malignancies: a multicenter study with 2-year follow-up
di Visconte, M. S., Santoro, G. A., Cracco, N., Sarzo, G., Bellio, G., Brunner, M., Cui, Z., & Matzel, K. E. (2018) · Techniques in Coloproctology · doi:10.1007/s10151-017-1745-2 · Cited by 19
Acupuncture of different treatment frequency in postprandial distress syndrome: A pilot randomized clinical trial
Wang, Y., Hou, Y., Yang, J., Wang, L., Shao, J., Zou, X., Yang, N., Huang, J., & Liu, C. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13812 · Cited by 19
Pharmacological basis of bergapten in gastrointestinal diseases focusing on H+/K+ ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs
Aslam, H., Khan, A., Qazi, N. G., Ali, F., Hassan, S. S. U., & BUNGAU, S. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1005154 · Cited by 18
The Influence of Alexithymia on Persistent Symptoms of Dyspepsia after Laparoscopic Cholecystectomy
Porcelli, P., Lorusso, D., Taylor, G. J., & Bagby, R. M. (2007) · The International Journal of Psychiatry in Medicine · doi:10.2190/r781-2897-7218-0r32 · Cited by 18
Cisapride treatment of constipation–predominant irritable bowel syndrome is not superior to placebo
Ziegenhagen, D. J., & Kruis, W. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03384.x · Cited by 18
Comprehension and awareness of symptoms in women with dyspepsia
Vakil, N. B., van Zanten, S. V., Chang, L., TOTH, G., SHERMAN, J., FRASER, M., & Cohard, M. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02699.x · Cited by 18
Patients’ perceptions on non‐specific effects of acupuncture: Qualitative comparison between responders and non‐responders
Ho, R. S. T., Ho, F. F., Adams, J., Cramer, H., Leung, B. M. Y., Ward, L., Zhang, Y., & Chung, V. C. (2021) · Integrative Medicine Research · doi:10.1016/j.imr.2021.100771 · Cited by 17
Clinical Trials of Probiotics in Patients With Irritable Bowel Syndrome: Some Points to Consider
Quigley, E. M. M. (2022) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm22012 · Cited by 17
Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS‐C
Camilleri, M., Lembo, A. J., Lavins, B. J., MacDougall, J. E., Carson, R. T., Williams, V. S. L., Nelson, L. M., Shiff, S. J., Currie, M. G., Kurtz, C. B., et al. (2014) · United European Gastroenterology Journal · doi:10.1177/2050640614555946 · Cited by 17
A randomised controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study)
Flik, C. E., van Rood, Y. R., Laan, W., Smout, A. J. P. M., Weusten, B. L. A. M., Whorwell, P. J., & de Wit, N. J. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-137 · Cited by 17
Effect of peroral esophageal myotomy for achalasia treatment: A Chinese study
Lü, B. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i18.5622 · Cited by 17
Depression Is Associated with Repeat Emergency Department Visits in Patients with Non-specific Abdominal Pain
Meltzer, A. C., Bregman, B. L., & Blanchard, J. (2014) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2013.7.15635 · Cited by 17
Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
Hamatani, T., Fukudo, S., Nakada, Y., Inada, H., Kazumori, K., & Miwa, H. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15907 · Cited by 16
FODMAP dietary restrictions in the management of children with functional abdominal pain disorders: A systematic review
Stróżyk, A., Horvath, A., & Szajewska, H. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14345 · Cited by 16
A dietitian‐led low‐FODMAP diet webinar: a pre–post study evaluating its impact on symptoms of irritable bowel syndrome
Colgan, A., Digby, K., Apekey, T. A., Elborough‐Whitehouse, I., Seamark, L., Radcliffe, O., Williams, M., & Hickson, M. (2023) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.13262 · Cited by 16
A meta-analysis of randomized controlled trials evaluating the effectiveness of fecal microbiota transplantation for patients with irritable bowel syndrome
Wang, Y., Hu, Y., & Shi, P. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03311-x · Cited by 19
Electroacupuncture plus on‐demand gastrocaine for refractory functional dyspepsia: Pragmatic randomized trial
Chung, V. C., Wong, C. H. L., Wu, X., Ching, J. Y. L., Cheung, W. K. W., Yip, B. H. K., Chan, K. L., Cheong, P. K., & Wu, J. C. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14737 · Cited by 16
Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores
Lackner, J. M., Jaccard, J. J., & Baum, C. (2012) · Value in Health · doi:10.1016/j.jval.2012.08.2207 · Cited by 17
Development and validation of a simple and multifaceted instrument, GERD-TEST, for the clinical evaluation of gastroesophageal reflux and dyspeptic symptoms
Nakada, K., Matsuhashi, N., Iwakiri, K., Oshio, A., Joh, T., Higuchi, K., & Haruma, K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i28.5216 · Cited by 16
The Autonomic Nervous System in Acupuncture for Gastrointestinal Dysmotility: From Anatomical Insights to Clinical Medicine
Yang, N., Xie, X., Yan, W., Liu, Y.-D., Wang, H.-X., Yang, L.-X., & Liu, C. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.107643 · Cited by 17
Comparison of the Efficacy of Buspirone and Placebo in Childhood Functional Abdominal Pain: A Randomized Clinical Trial
Badihian, N., Yaghini, O., Badihian, S., Shahsanai, A., & Saneian, H. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000589 · Cited by 15
Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial
Zheng, Y., Ching, J., Cheng, C.-W., Lam, W., Chan, K.-L., Zhang, X., Lam, P.-Y., Wu, X.-Y., Zhong, L., Cao, P.-H., et al. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00530-2 · Cited by 14
An Herbal Medicine, Yukgunja‐Tang is more Effective in a Type of Functional Dyspepsia Categorized by Facial Shape Diagnosis: A Placebo‐Controlled, Double‐Blind, Randomized Trial
Ko, S., Park, J.-W., Lee, J., Lee, J. E., Ha, N.-Y., Nam, S.-U., Lee, J. D., Jeon, S.-H., Kim, J.-W., Kang, C., et al. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/8546357 · Cited by 15
Methodological Challenges to Treatment Trials for Recurrent Abdominal Pain in Children
Ball, T. M., & Weydert, J. A. (2003) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.157.11.1121 · Cited by 15
Short-Term Daily Intake of Polydextrose Fiber Does Not Shorten Intestinal Transit Time in Constipated Adults: A Randomized Controlled Trial
Duncan, P. I., Enters-Weijnen, C. F., Emami, N., McLean, P. G., Nunes, T., Beaumont, M., Crabbé, R., Whelan, K., Scott, S. M., de Wit, N. J., et al. (2018) · Nutrients · doi:10.3390/nu10070920 · Cited by 15
Are withdrawal trials in paediatric rheumatic disease helpful?
Lehman, T. J. A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60999-x · Cited by 15
Gastrointestinal well-being in subjects reporting mild gastrointestinal discomfort: characteristics and properties of a global assessment measure
Guyonnet, D., Naliboff, B. D., Rondeau, P., Mayer, E. A., & Chassany, O. (2013) · British Journal Of Nutrition · doi:10.1017/s0007114513000275 · Cited by 15
Understanding and Treatment of Chronic Abdominal Pain in Pediatric Primary Care
Schurman, J. V., Kessler, E. D., & Friesen, C. A. (2014) · Clinical Pediatrics · doi:10.1177/0009922814545162 · Cited by 14
The daily diary and the questionnaire are not equivalent for the evaluation of bowel habits
Bellini, M., Bove, A., Sormani, M. P., Battaglia, E., Bocchini, R., Alduini, P., Bassotti, G., Bruzzi, P., & Pucciani, F. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.04.008 · Cited by 14
Robust Regression and Optimal Transport Methods to Predict Gastrointestinal Disease Etiology From High Resolution EGG and Symptom Severity
Agrusa, A. S., Kunkel, D. C., & Coleman, T. P. (2022) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2022.3167338 · Cited by 14
Predictors of acid suppression success in patients with chronic laryngitis
Wang, A. J., Liang, M., Jiang, A., Lin, J.-K., Xiao, Y., Peng, S., Chen, J., Wen, W., & Chen, M. H. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01873.x · Cited by 14
Pitfalls in designing trials of functional dyspepsia: the ascent and demise of itopride
van Zanten, S. J. O. V. (2008) · Gut · doi:10.1136/gut.2007.139923 · Cited by 14
Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial
Sadrin, S., Sennoune, S. R., Gout, B., Marque, S., Moreau, J., Grillasca, J., Pons, O., & Maixent, J. M. (2017) · Cellular and Molecular Biology · doi:10.14715/cmb/2017.63.9.21 · Cited by 15
Effect of a low-FODMAP diet for the management of functional abdominal pain disorders in children: a study protocol for a randomized controlled trial
Stróżyk, A., Horvath, A., Muir, J. G., & Szajewska, H. (2021) · Nutrition Journal · doi:10.1186/s12937-020-00656-3 · Cited by 13
In Search of Mechanisms of Change in Treatment Outcome Research: Mediators and Moderators of Psychological and Pharmacological Treatments for Irritable Bowel Syndrome
Labus, J. S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.052 · Cited by 13
UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
Yiannakou, Y., Agrawal, A., Allen, P. B., Arebi, N., Brown, S. R., Eugenicos, M. P., Farmer, A. D., McLain-Smith, S., McLaughlin, J., Sanders, D. S., et al. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818798791 · Cited by 12
Perilla Extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study
Buchwald‐Werner, S., Fujii, H., Reule, C., & Schön, C. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-173 · Cited by 12
Comparative effectiveness of biofeedback and injectable bulking agents for treatment of fecal incontinence: Design and methods
Bharucha, A. E., Gantz, M. G., Rao, S. S. C., Lowry, A. C., Chua, H. K., Karunaratne, T. B., Wu, J. M., Hamilton, F. A., & Whitehead, W. E. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106464 · Cited by 13
Self-citation
Experimental Models of Stress and Pain: Do They Help to Develop New Therapies?
Bradesi, S., & Mayer, E. A. (2009) · Digestive Diseases · doi:10.1159/000268122 · Cited by 13
Current indications for acid suppressants in dyspepsia
Bytzer, P. M., & Talley, N. J. (2001) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2001.0186 · Cited by 12
The development and assessment of biological treatments for children
Smith, E. M. D., Foster, H., & Beresford, M. W. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12406 · Cited by 11
Effectiveness of diet, psychological, and exercise therapies for the management of bile acid diarrhoea in adults: A systematic review
McKenzie, Y. A., Sremanakova, J., Todd, C. J., & Burden, S. T. (2022) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.13005 · Cited by 10
Pictograms are more effective than verbal descriptors in Spanish for bloating and distension
Rabago, R. E., Bonilla, A., Escamilla‐Diego, E., la Tijera, F. H., & Schmulson, M. J. (2022) · Neurogastroenterology & Motility · doi:10.1111/nmo.14364 · Cited by 11
Self-citation
Optimizing educational methods for the low FODMAP diet in disorders of gut–brain interaction: A feasibility randomized controlled trial
Dimidi, E., McArthur, A. J., White, R., Whelan, K., & Lomer, M. C. E. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14640 · Cited by 12
Low FODMAP diet in Egyptian patients with Crohn's disease in remission phase with functional gastrointestinal symptoms
El-Husseiny, M. H., Amine, A. K., Salem, O. E., Tayel, D. I., & Elsayed, E. A. (2018) · JGH Open · doi:10.1002/jgh3.12037 · Cited by 11
Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome
Arrouk, R., Herdes, R. E., Karpinski, A. C., & Hyman, P. E. (2018) · Pediatric Health Medicine and Therapeutics · doi:10.2147/phmt.s159925 · Cited by 11
“the attention given to enrolled patients, including detailed explanation, reassurance, close monitoring, and ready access to the researchers, which may produce a therapeutic effect, a bias leading to an error in estimating the treatment effect.(14) In addition, there was slight difference in age and number of male and…”
Gut-directed hypnotherapy versus standard medical treatment for nausea in children with functional nausea or functional dyspepsia: protocol of a multicentre randomised trial
Browne, P. D., den Hollander, B., Speksnijder, E. M., van Wering, H. M., Ten, W. T. A., George, E. K., Groeneweg, M., Bevers, N., Wessels, M. M. S., van den Berg, M. M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024903 · Cited by 11
Minimal-Contact Versus Standard Cognitive Behavioral Therapy for with Irritable Bowel Syndrome: Cost-Effectiveness Results of a Multisite Trial.
Dunlap, L. J., Jaccard, J., & Lackner, J. (2021) · Annals of Behavioral Medicine · doi:10.1093/abm/kaaa119 · Cited by 10
Efficacy of an activated charcoal–simethicone combination in dyspeptic syndrome: Results of a placebo-controlled prospective study in general practice
Lecuyer, M., Cousin, T., Monnot, M.-N., & Coffin, B. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2008.09.021 · Cited by 11
Economic evaluation of empirical antisecretory therapy versusHelicobacter pylorifor management of dyspepsia: A randomized trial in primary care
Jarbøl, D. E., Bech, M., Kragstrup, J., Havelund, T., & de Muckadell, O. B. S. (2006) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462306051269 · Cited by 11
Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial
Cristofori, F., Calabrese, F. M., Iacobellis, I., Santamaría, M., Celano, G., Ferrocino, I., Sabato, E. D., Pergola, R., Dargenio, V. N., Paulucci, L., et al. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70154 · Cited by 12
Guideline Recommendation for Endpoints Used in Clinical Trials for Functional Dyspepsia
Lee, H. H., Jung, H., & Choi, M. (2018) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2018.72.4.170 · Cited by 10
Adult celiac disease with persistent IBS-type symptoms: a pilot study of an adjuvant FODMAP diet.
Trott, N., Rej, A., Coleman, S. H., & Sanders, D. S. (2021) · Gastroenterology and hepatology from bed to bench. · Cited by 9
Développer un médicament dans le syndrome de l’intestin irritable : une mission impossible ?
Duracinský, M., & Chassany, O. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(09)71522-2 · Cited by 10
Gut feelings about diabetes and GLP ‐1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders
Rayner, C. K., Jones, K. L., Wu, T., & Horowitz, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12822 · Cited by 9
Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain – not otherwise specified: a systematic review
Rexwinkel, R., Zeevenhooven, J., van Etten‐Jamaludin, F. S., Benninga, M. A., & Tabbers, M. M. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1574295 · Cited by 9
Outcome of a public consultation on the discussion paper for the revision of the guidance on the scientific requirements for health claims related to gut and immune function
(EFSA), E. F. S. A. (2015) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2015.en-758 · Cited by 9
Systematic review: Disease‐specific instruments to assess gastrointestinal symptoms in functional dyspepsia
Smeets, F. G. M., Masclee, A., Conchillo, J. M., & Keszthelyi, D. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13327 · Cited by 9
The role of mood state and emotion regulation in the discrepancy between gastrointestinal symptom burden recorded prospectively and via recall questionnaire
Jones, M., Yun, G., Wass, F., Rixon, H., Shah, A., Walker, M. M., Koloski, N. A., Holtmann, G., Talley, N. J., & Beath, A. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14304 · Cited by 9
Green Light from the FDA for New Drug Development in Irritable Bowel Syndrome and Functional Dyspepsia
Talley, N. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.295 · Cited by 9
The efficacy of Combizym in the treatment of Chinese patients with dyspepsia: a multicenter, randomized, placebo‐controlled and cross‐over study
Ran, Z. H., Yao Zong, Y. U. A. N., Li, Z. S., Wang, J. Y., Zong, C.-H., Xie, W., Zheng, P., Chen, S., Zhan, X. B., Chen, S. Y., et al. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2008.00361.x · Cited by 9
Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome
Lea, R., & Whorwell, P. J. (2004) · Drug Safety · doi:10.2165/00002018-200427040-00002 · Cited by 9
Psychosocial factors in functional gastrointestinal disorders: an evolving phenomenon
Olden, K. W. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01112.x · Cited by 9
Double‐blind, randomized, 8‐week multicenter study of the efficacy and safety of STW 5‐II versus placebo in functional dyspepsia
Vinson, B. R., Fink, C., Wargenau, M., Talley, N. J., & Holtmann, G. (2024) · JGH Open · doi:10.1002/jgh3.13054 · Cited by 8
“29 The prede ﬁ ned endpoint of response rate re ﬂ ects an adequate relief endpoint with clinically meaningful symptom improvement recommended for FGIDs in that time.”
Method
Quality of life in irritable bowel syndrome: measurement techniques and relevance of current knowledge
Simrén, M. (2003) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.3.1.75 · Cited by 8
Electroacupuncture to treat gastroesophageal reflux disease: study protocol for a randomized controlled trial
Han, G., Leem, J., Lee, H., & Lee, J. (2016) · Trials · doi:10.1186/s13063-016-1371-8 · Cited by 8

Authors: Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B.
Affiliations: St. Michael's Hospital (CA)
Universitair Ziekenhuis Leuven (BE)
Mayo Clinic (US)
National University of Singapore (SG)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Hospital General de México (MX)
University of North Carolina at Chapel Hill (US)
Cedars-Sinai Medical Center (US)
Corresponding author: Tack, Jan
ORCID: Tack, Jan
Crowell, Michael D.
Gwee, Kok Ann
Schmulson, Max J.
Whitehead, William E.
Spiegel, Brennan
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2016-05
Volume: 150
Issue: 6
Pages: 1469-1480.e1
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2016.02.010
OpenAlex: W2065994042
Cited by: 550
References: 151
Citations by year: 2026: 7 · 2025: 7 · 2024: 17 · 2023: 12 · 2022: 19 · 2021: 25 · 2020: 22 · 2019: 22 · 2018: 31 · 2017: 22 · 2016: 20
FWCI: 5.29
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Keywords: functional gastrointestinal disorders, clinical trial design, sham procedure, expectancy effects, nocebo, patient-reported outcome measures, intention-to-treat analysis, CONSORT guidelines, clinical trial registration, regulatory guidelines
MeSH terms: Gastrointestinal Diseases, Research Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Design of Treatment Trials for Functional Gastrointestinal Disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks